Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$1.77M+277.61%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marvin L. Slosman
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 127
- Beta
- 0.82
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -10.76
Financials
Revenue
$1.77M+277.6%Net Income
$-14.32MEBITDA
$-14.17MFree Cash Flow
$-11.22MEPS (diluted)
$-0.19Shares Outstanding (diluted)
73.47M+144051862.7%Operating Expenses
$13.67MCash & Debt
$30.42MReturn of Capital
$0.00Revenue by Segment (annual)
$5.17MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.98M | $-48.79M | $-0.76 |
| 2024 | $7.01M | $-32.01M | $-0.76 |
| 2023 | $6.21M | $-19.92M | $-0.82 |
| 2022 | $5.17M | $-18.49M | $-2.35 |
| 2021 | $4.50M | $-14.92M | $-2.03 |
| 2020 | $2.48M | $-10.54M | $-6.90 |
| 2019 | $3.72M | $-10.04M | $-72.00 |
| 2018 | $3.60M | $-7.24M | $-247.50 |
| 2017 | $2.76M | $-8.44M | $-4265.93 |
| 2016 | $1.89M | $-8.46M | $-151089.29 |
| 2015 | $2.31M | $-15.59M | $-1416818.18 |
| 2014 | $2.82M | $-25.09M | $-4182500.00 |
| 2013 | $4.87M | $-29.26M | $-5851600.00 |
| 2012 | $5.35M | $-17.60M | $-9217.92 |
Valuation
NSPRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.75%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·15d ago·Neutral
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 -
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of…
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C.
View source ↗ - Newsseekingalpha.com·49d ago·Positive
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
… Financial Results - Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026. Recent Business Highlights: Generated revenue of $1.8 million in the second quarter of 2026, in line with the second…
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-0.15 per share
Typical surprise +5.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 17$-0.17 vs $-0.20beat
- Mon, May 4$-0.16 vs $-0.19beat
- Wed, Mar 18$-0.14 vs $-0.22beat
- Tue, Nov 4$-0.17 vs $-0.17beat
- Mon, Aug 4$-0.26 vs $-0.24miss
- Fri, May 9$-0.22 vs $-0.17miss
Estimates and results for NSPR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NSPR officers and directors.
- Bought
- $675k
- Sold
- $289k
19 trades
24 trades
- Stuka Paulbought
- Gleason Shane Thomassold
- Stuka Paulbought
- Stuka Paulbought
- Slosman Marvinbought
- Stuka Paulbought
- Stuka Paulbought
- Ward Scott R.bought
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NSPR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.